In recent years, as more and more people have become aware of mental illness and the treatments available for it, the development of psychedelics has accelerated. The goal of establishing it as a mainstream treatment has been attempted on several occasions.

2020 has changed the way everything works, along with people experiencing and needing help for mental health issues in heightened amounts. As a result, early-stage psychedelic firms are holding investors' attention, especially in 2021. If you are one of them, look at these psychedelic company stocks to buy in 2021.

1. Bright Minds Biosciences

For an investor and someone who knows the importance of mental health, Bright Minds Biosciences looks like an interesting choice for the investment in psychedelic company stocks. In 2021 February, the company has announced its listing on Canadian Stock Exchange, and investors are rallying behind its stocks.

Bright Minds Biosciences stocks, on the other hand, are a smart investment because of their diverse portfolio of treatments and next-generation drugs and the fact that they are the only patented manufacturer of selective serotonergic agents. Bright Minds is also focusing on developing pharmaceuticals and therapies that will replace opiate prescriptions in the future.

2. Mind Medicine

No matter how drugs help in mental health issues, the truth is that habit-forming drugs are not the future. But investing in psychedelics which will bring long-term relief only with one dose and without counterproductive side effects, looks quite promising.

This is why Mind Medicine becomes a good choice among other psychedelic company stocks - for their unique psychedelic therapy programs with more than one drug in their pipeline.

3. Eleusis

Based in London, Eleusis is a biotechnology company known for being the first privately-held clinical-stage life-sciences company. They are testing micro-dosed LSD for the implications of Alzheimer’s.

Due to higher adoption rates and comparatively cheaper drug development, investors focusing on short-term success in psychedelics should focus on companies with micro-dosing applications.

4. Numinus Wellness

The cultivation license for producing and extracting psilocybin started with Numinus Wellness, and it also has a license for import and export of other psychedelics. The company is trying to establish psychedelic-assisted therapies accessible across various health centers.

With over $165 million market capitalization, Numinous Wellness announced its plan to buy Neurology Centre of Toronto in cash and shares. Their primary goal is to transform its treatments that focus on psychedelics.

5. Atai Life Sciences

Atai Life Sciences is a biopharma company based in Germany that works on the development of psychedelic drugs. One of the notable investors of Atai Life Sciences is Peter Thiel. The recently becoming public company’s shares have offered over 6.9% returns.

Conclusion

With the continuous decriminalization and legalization of psychedelics, as well as a growing body of research demonstrating their effectiveness in treating mental health concerns, psychedelics are quickly moving into the mainstream of medical treatment. However, this does not rule out the possibility of psychedelic drug stocks in the future. And for those who remain interested in investing in psychedelic drug stocks, their companies' selection will depend on their personal preferences.

Learn more information on brightmindsbio.com